Opinion
Video
Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
Author(s):
Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.
Video content above is prompted by the following:
- How do you typically approach biomarker testing for advanced ovarian cancer?
- When do you test and what type of testing do you perform?
- Which biomarkers do you generally access (e.g., BRCA1/2, HRD, etc) and how do results help guide your treatment approach?
- Briefly review frontline maintenance therapy options for advanced ovarian cancer and discuss key factors that drive your selection among available therapies.
- How do BRCA and HRD statuses influence your choice of maintenance therapy?
- When may you opt for a combination (PARPi + bev) vs monotherapy approach?
Related Videos
Related Content
